Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 30Mesothelioma 20Solid Tumor 18Mesothelioma, Malignant 18Advanced Solid Tumors 18Solid Tumors 16Solid Tumor, Adult 11Melanoma 10Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 8Colorectal Neoplasms 8Retinoblastoma 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Cholangiocarcinoma 6Advanced Malignant Solid Neoplasm 6Triple Negative Breast Neoplasms 5Sarcoma 5Stomach Neoplasms 4Pancreatic Neoplasms 4Malignant Solid Neoplasm 4Esophageal Neoplasms 4Advanced or Metastatic Solid Tumors 4Small Cell Lung Carcinoma 3Neoplasms 3Malignant Solid Tumor 3Locally Advanced or Metastatic Solid Tumors 3Hematopoietic and Lymphatic System Neoplasm 3

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Rare Malignant Solid Neoplasm × Other solid neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡